agenT-797
Solid Tumors
Key Facts
About MiNK Therapeutics
MiNK Therapeutics is at the forefront of developing novel, allogeneic iNKT cell therapies, a promising class of living medicines. The company's platform is designed to overcome key limitations of traditional cell therapies by offering an 'off-the-shelf' product that does not require patient matching or preconditioning. With over 70 patients treated across its programs in solid tumors and severe ARDS, MiNK has demonstrated initial clinical proof-of-concept and is now focused on advancing its pipeline and scaling its manufacturing technology. Its strategic direction involves leveraging the unique biology of iNKT cells for both oncology and inflammatory diseases.
View full company profileAbout MiNK Therapeutics
MiNK Therapeutics is at the forefront of developing novel, allogeneic iNKT cell therapies, a promising class of living medicines. The company's platform is designed to overcome key limitations of traditional cell therapies by offering an 'off-the-shelf' product that does not require patient matching or preconditioning. With over 70 patients treated across its programs in solid tumors and severe ARDS, MiNK has demonstrated initial clinical proof-of-concept and is now focused on advancing its pipeline and scaling its manufacturing technology. Its strategic direction involves leveraging the unique biology of iNKT cells for both oncology and inflammatory diseases.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Phase 2 |